# Prevention of Delirium in Intensive Care by Melatonin

> **NCT03524937** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 355 (actual)

## Conditions studied

- Mechanically Ventilated Patients

## Interventions

- **DRUG:** MELATONIN (HIGH DOSE)
- **DRUG:** MELATONIN (LOW DOSE)
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT03524937
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2021-05-01
- **Final completion:** 2021-05-20
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524937, "Prevention of Delirium in Intensive Care by Melatonin". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03524937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*